Pharmaceutical Exclusivity
Navigating the Complex and Changing Rules

Thursday, Feb. 27, 2020 • 1:30 p.m. - 3:00 p.m. EST

Get up to speed on the FDA exclusivity rules and critical developments.

Not knowing the latest developments could cause major delays in development, lose years of protection and cost your company millions of dollars.

Join us on Feb. 27 to get the latest on pharmaceutical exclusivity and how to navigate the complex changes.

Webinar Takeaways:

  • Familiarize yourself with the nuances of the new standard governing the scope of 3-year clinical investigation exclusivity and how that can affect FDA approval decisions, particularly 505(b)(2) applications
  • Assess recent developments regarding orphan drug exclusivity, such as when exclusivity can be revoked and how FDA allows companies to evergreen it
  • Critically evaluate the impacts of the upcoming March 23, 2020 transition of several important protein products, such as insulin, from being regulated as drugs to being regulated as biologics
  • Get a sense of current legislative proposals aimed at exclusivity, including 180-day generic drug exclusivity, orphan drug exclusivity and other products

Get your product to market! Join us by registering today.

Who Will Benefit

  • Brand pharmaceutical companies
  • Generic pharmaceutical companies
  • Brand biotech companies
  • Biosimilar developers
  • Investors
  • Quality, regulatory and compliance specialists
  • Attorneys
  • Consultants
  • Strategic planners

Webinar plus USB Audio Recording/Transcript
Learn more

$487

add to cart

Webinar only
Learn more

$287

add to cart

24/7 Encore plus USB Audio Recording/Transcript
Learn more

$487

add to cart

24/7 Encore Presentation
Learn more

$287

add to cart

USB Audio Recording/Transcript
Learn more

$287

add to cart

 

Meet Your Presenter

Scott M. Lassman

Principal
Lassman Law+Policy

Your webinar leader, Scott M. Lassman, is the Principal at Lassman Law+Policy, a boutique law firm located in Washington, D.C., that focuses on solving its clients’ most complicated FDA-related problems. Scott provides strategic advice and advocacy to small, mid-size, and large pharmaceutical, biotechnology, and medical device companies, as well as the trade associations that represent them and the investors who fund them. His practice covers all aspects of FDA regulatory law, with a special focus on exclusivity, biosimilars, product approval, and policy matters.
 
Scott also has extensive experience with the FDA Citizen Petition process and, when necessary, litigating FDA disputes in federal court. He has successfully protected his clients’ interests through litigation in a wide variety of matters, including Hatch-Waxman exclusivity, 180-day exclusivity, pediatric exclusivity, user fees, and approval requirements. Scott is author of the Exclusivity Rules blog, which focuses on the written and unwritten rules governing FDA’s exclusivity decisions.

MII logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 | Fax 703.538.7676 | Toll free 888.838.5578 | Email customerservice@fdanews.com

© 2020 FDAnews